Engflag

Telmicard

Quick links to important sections

Telmicard

Telmicard_EN

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Hypotensive

Treatment option: Arteriosclerosis/Atherosclerosis, Heart Disease, Hypertension, Peripheral Arterial Disease, Cerebrovascular Accident, Coronary Heart Disease, Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Telmicard

Quick Facts

Property Description
Active ingredient Telmisartan
Form Tablet (for oral administration)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Management of systemic hypertension
Origin Synthetic non-peptide compound

What Type of Medicine is Telmicard? (Classification and Active Substance)

Telmicard is a prescription-only medication that contains the active substance Telmisartan. This compound is classified as an Angiotensin II Receptor Blocker (ARB), a group of cardiovascular drugs utilized for the management of high blood pressure, or systemic hypertension. Telmisartan is a chemically synthesized non-peptide compound derived from a Benzimidazole-7-carboxylic acid structure.

A key feature distinguishing Telmisartan from many other ARBs is its long terminal elimination half-life, which is approximately 24 hours. This duration of action ensures sustained blood pressure control throughout the entire daily dosing interval, addressing a major goal in chronic hypertension management.

Telmicard: Composition, Form, and Origin

Telmicard is supplied for oral administration in the pharmaceutical preparation of a compressed tablet, functioning as a single active ingredient product. The active component, Telmisartan, is a synthetic compound produced through defined laboratory processes, ensuring the stability and purity of its therapeutic properties.

The tablet structure combines the active Telmisartan with necessary inactive components, or excipients, such as sorbitol and magnesium stearate, required for proper formulation and consistent bioavailability. Telmisartan is an orally active and specific angiotensin II receptor antagonist, reflecting the high specificity of the active compound to its intended biological target.

How Does Telmicard Generally Help the Body? (High-Level Purpose)

The fundamental benefit of Telmicard is its ability to promote the relaxation and widening of the body's blood vessels. This action is achieved by antagonizing a key signal that normally causes arteries to constrict, leading directly to a reduction in systemic vascular resistance.

By lessening the overall resistance against which blood flows, the drug decreases the pressure exerted on the artery walls. This sustained reduction in blood pressure alleviates strain on the heart, which is the foundational objective in the medical strategy for managing systemic hypertension and cardiovascular risk reduction.

Regulatory References

  1. Telmisartan: MedlinePlus Drug Information
  2. Micardis EPAR - Summary for the public

What side effects are possible with Telmicard?

Possible side effects and safety information

The safety characteristics of Telmicard (Telmisartan) are classified and communicated according to standards set by government regulatory authorities. Adverse reactions are grouped by frequency and the body's physiological systems involved, providing a structured summary of the medicine’s risk profile.

Adverse effects are documented using standard frequency tiers, reflecting clinical trial data and post-marketing reports:

  • Common (ge 1%): Reactions observed frequently include back pain, dizziness, upper respiratory tract infection, sinusitis, diarrhea, and fatigue.
  • Uncommon (0.1%-1%): Less frequent effects include hypotension (low blood pressure), syncope, bradycardia, cough, and gastrointestinal effects like abdominal pain and nausea.
  • Rare (<0.1%): Serious but rarely reported post-marketing events include anaphylactic reaction (severe allergic reaction) and interstitial lung disease.

Serious Adverse Reactions and Safety Constraints

Official labeling defines specific high-risk conditions. The most serious risk documented is Fetal/Neonatal Toxicity; use during the second and third trimesters of pregnancy is strictly contraindicated due to the risk of injury or death to the developing fetus. Other serious reactions include angioedema (swelling of the face, tongue, or throat) and hyperkalemia (elevated potassium levels), which is of particular concern in patients with renal impairment.

Safety notes specify constraints for certain conditions. For instance, Telmicard is not recommended in severe hepatic impairment. Caution is also documented for patients with conditions such as severe aortic or mitral stenosis, and for those who are volume- or salt-depleted, who may experience more pronounced hypotension at the beginning of treatment.

Overdose and Emergency Response

Overdose Manifestations and Complications

An overdose of Telmicard (telmisartan) is primarily expected to result in an exaggeration of its blood pressure-lowering effects, according to regulatory documents. The most likely presentation is symptomatic hypotension (profoundly low blood pressure), which may be accompanied by changes in heart rhythm, such as an abnormally fast heart rate (tachycardia) or an abnormally slow heart rate (bradycardia). Symptoms associated with severe low blood pressure, including dizziness and loss of consciousness (syncope or fainting), are also documented.

The official regulatory profile lists more severe outcomes that may occur, including oliguria (low urine output) and the risk of developing acute renal failure secondary to the excessive effect on the renin-angiotensin-aldosterone system.

Required Emergency Actions

Immediate medical attention is mandated by health authorities if an overdose is suspected. Specifically, regulatory information directs individuals to call emergency services immediately if the affected person has collapsed, is experiencing trouble breathing, or cannot be awakened. Overdose management is officially defined as symptomatic and supportive treatment.

Management Constraints

Regulatory labeling explicitly states that no specific antidote is known for telmisartan. Due to the drug’s high plasma protein binding, it is not removed from the body by hemodialysis. Management procedures include placing the patient in a supine position and, if necessary, administering intravenous normal saline to manage symptomatic hypotension.

Therapeutic Uses of Telmicard

What Telmicard Treats: Main Uses and Benefits

Telmicard (Telmisartan) is commonly used to address three core therapeutic domains.

This medication is utilized for the long-term control of essential hypertension, a condition presenting with systemic imbalance and chronic, often unnoticed, symptoms that create noticeable physiological strain. It is commonly used for managing the risk of symptoms associated with acute or disruptive episodes, such as those related to heart attack and stroke, in adult patients with a high-risk profile. Furthermore, the drug is relevant for easing symptoms linked to organ-specific functional stress, such as kidney complications in patients with Type 2 diabetes who also have high blood pressure.

The primary therapeutic benefit contributes to maintaining stable blood pressure control, which may assist with managing the chronic systemic imbalance that is linked to organ-specific functional stress. For high-risk individuals, the therapy contributes to easing the overall symptom load associated with conditions that involve episodic or fluctuating manifestations.

The treatment supports general well-being during symptomatic phases linked to organ-specific functional stress as part of a long-term, supportive therapy.

Quick Fact Support for Chronic Conditions
Main Therapeutic Focus Managing chronic systemic imbalance
Primary Condition Essential hypertension
Use in High-Risk Patients To manage the risk of major cardiovascular events
Specific Benefit Assists with managing the progression of functional stability that becomes affected

Regulatory References

  1. NIH MedlinePlus overview on Telmisartan

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Telmicard

Telmicard (Telmisartan) eligibility is strictly defined by regulatory documents, distinguishing between approved use, absolute contraindications, and restricted conditions.

Eligibility scope Status as per Labeling
Populations for whom use is allowed Adults (18+). Also approved for cardiovascular risk reduction in adults 55 years and older. No dose adjustment is generally necessary for older adults (65+) [FDA/EMA].
Populations for whom use is contraindicated Pregnancy (second and third trimesters). Severe Hepatic Impairment. Biliary Obstructive Disorders (e.g., cholestasis). Known Hypersensitivity to Telmisartan. Diabetic patients or those with renal impairment (GFR < 60) concurrently taking Aliskiren [FDA/EMA].
Populations for whom use is restricted Mild-to-Moderate Hepatic Impairment: Use with caution; maximum dose typically limited to 40 mg. Volume- or Salt-Depleted Patients: Should be corrected prior to initiation. Aortic/Mitral Stenosis or Obstructive Hypertrophic Cardiomyopathy: Special caution is indicated [EMA].

Age-Related Eligibility Rules

Use in children and adolescents (under 18 years) is not recommended, as safety and efficacy have not been established by regulatory authorities. The medicine is contraindicated in the later stages of pregnancy and is not recommended during the first trimester or while breastfeeding [FDA/EMA]. Use in patients with Primary Aldosteronism is also not recommended.

What should I know about interactions with other medicines?

Telmicard Interactions with other medicines and products

Telmicard (Telmisartan) may interact with several medicinal products and substance categories, primarily through additive effects on blood pressure or electrolytes, and through changes to the clearance of co-administered drugs.

Interaction Type Interacting Substances and Official Restrictions
Formally Contraindicated Co-administration with Aliskiren is prohibited in patients with mathbfdiabetes or in patients with mathbfrenal impairment (GFR <60 mL/min/1.73 m^2) due to increased risk of hyperkalemia and hypotension.
Exposure-Altering (PK) Co-administration with mathbfLithium may significantly increase serum lithium concentrations, leading to potential toxicity. Telmisartan also increases the mathbfplasma concentrations of Digoxin, a change linked to the inhibition of P-glycoprotein.
Pharmacodynamic (PD) Effects The use of mathbfPotassium-raising agents (including potassium supplements and salt substitutes) is restricted due to an increased risk of mathbfhyperkalemia. Concomitant use with NSAIDs may reduce Telmicard’s antihypertensive effect and increase the risk of mathbfworsening renal function.

Telmisartan’s systemic exposure is also affected by certain conditions: the official label notes that mathbfplasma concentrations are increased in patients with mathbfhepatic insufficiency. The drug can be taken mathbfwith or without food. These restrictions and documented outcomes constitute the official regulatory profile for co-administration.

Mechanism of Action

Telmisartan acts through a dual pharmacodynamic mechanism, engaging two distinct molecular pathways that influence cardiovascular and metabolic signaling.

Selective AT1 Receptor Blockade

Telmisartan primarily functions by selectively blocking the Angiotensin II Type 1 ( AT1) receptor. This mechanistic domain interrupts the Renin-Angiotensin System (RAS) cascade. Angiotensin II, a pressor agent, is prevented from binding to and activating the AT1 receptor on vascular smooth muscle and other tissues. This inhibition suppresses signals for vasoconstriction, aldosterone release, and sympathetic nerve activity within the vascular pathways.

Partial PPAR-Gamma Agonism

In addition to its primary action, Telmisartan is recognized as a partial agonist of Peroxisome Proliferator-Activated Receptor-gamma ( PPAR-gamma). This nuclear receptor regulates metabolic and inflammatory genes. Engaging this domain modulates intracellular pathways associated with insulin sensitivity, glucose and lipid metabolism, and chronic inflammation. This effect influences anti-inflammatory and antioxidative signaling processes at the cellular level.

Dosage and Administration Information

How to use Telmicard: Official Administration Guidelines

Telmicard (telmisartan) is administered orally as a tablet and is intended for once daily use. The medicine should be taken at approximately the same time each day, providing consistent management throughout the daily interval.

Instruction Detail
Route of Administration Oral (tablet form in 20 mg, 40 mg, and 80 mg strengths).
Standard Dosing Regimens The usual starting dose for essential hypertension is 40 mg once daily; the dose range extends from 20 mg up to a maximum of 80 mg once daily. For cardiovascular risk reduction, the standard administration is a fixed dose of 80 mg once daily.
Intake Conditions May be administered with or without food, taken with liquid.
Dose Adjustments For patients with mild to moderate hepatic impairment, the daily dose must not exceed 40 mg. No initial dosage adjustment is required for the elderly or those with mild to moderate renal impairment.

The proper use protocol requires specific handling of the tablet: due to its moisture-sensitive (hygroscopic) nature, it must be kept in its sealed blister pack and removed immediately prior to administration. In the event of a missed dose, the protocol is to skip the forgotten dose entirely and take the next scheduled dose at the usual time; double dosing is not recommended. This structured regimen defines the long-term, continuous approach to using the medicine, with the maximum clinical effect achieved after four to eight weeks.

Recent Clinical Evidence

Telmicard: Recent Clinical Evidence

This summary describes the structure of the clinical research conducted for Telmicard, detailing the types of studies and the outcomes researchers chose to measure. The information provided reflects only the research context.

Evidence for use in Essential Hypertension

Research for the clinical condition of high blood pressure, characterized by a systemic imbalance, is based on Randomized Controlled Trials (RCTs) and Ambulatory Blood Pressure Monitoring (ABPM) studies. Researchers measured changes in clinic-measured systolic and diastolic blood pressure levels (SBP/DBP) and observed blood pressure measurements throughout the 24-hour interval. Findings describe the patterns observed in adult cohorts with essential hypertension. Follow-up durations were generally short to intermediate term, often lasting 6 to 12 weeks to complete the defined study period for blood pressure measurements.

Evidence for use in Cardiovascular Risk Reduction

Research exploring Telmicard’s role in the risk of major disruptive episodes, such as stroke or heart attack, was conducted through large-scale, international, and long-term RCTs (e.g., ONTARGET and TRANSCEND). Researchers measured complex, major composite endpoints, including cardiovascular death, non-fatal stroke, and non-fatal myocardial infarction (MI). The primary research programs evaluated high-risk adults, generally aged 55 and older, with documented vascular disease or Type 2 diabetes with evidence of organ involvement.

Evidence for Organ-Specific Functional Stability and Research Gaps

Studies have explored research questions related to outcomes linked to physiological strain in specific organs, particularly the heart and kidneys, often derived from secondary analyses. Research examined changes in markers of left ventricular mass index (LVMI) and monitored the progression of microalbuminuria. However, evidence regarding these specific organ outcomes and long-term effects are not fully established for all possible secondary endpoints. For instance, in the high-risk cohort intolerant to ACE inhibitors, the primary composite outcome in the key trial did not establish a clear difference in measurements when compared to the placebo group.

Key Studies & References

  1. Telmisartan Drug Information (MedlinePlus)
  2. Angiotensin II Receptor Blockers (ARBs) Drug Class Review: Efficacy and Comparative Safety

Frequently Asked Questions (FAQ)

Common questions about Telmicard (FAQ)

Q: How long does it take for Telmicard to start working?

Telmicard is often reported to begin showing its effects within 2 to 4 weeks of consistent use. Some patients may begin to notice changes or improvements in symptoms around this timeframe. Stopping medication, even if symptoms improve, should only be done under the guidance of a healthcare professional. The full therapeutic benefits are typically observed after 6 to 8 weeks.

Q: Can I take Telmicard with alcohol?

Official label information for Telmicard often advises caution or avoidance of alcohol.

The combination is generally understood to potentially increase the severity of certain central nervous system side effects, such as drowsiness or dizziness. To understand the risk in your specific situation, it is best to consult with a healthcare professional.

Q: What should I do if I miss a dose of Telmicard?

Instructions for managing a missed dose should be based on the specific prescribing information or advice from a healthcare provider. Prescribing information typically outlines a specific course of action, such as taking the dose as soon as it's remembered (unless it's close to the next dose).

Never take a double dose to make up for a missed one. If there is uncertainty or if multiple doses are missed, it is recommended to consult a healthcare provider for specific advice.

How should Telmicard be stored and disposed of?

Storage and Disposal Requirements

Telmisartan tablets must be stored at Controlled Room Temperature, which is defined as 20^circ to 25 C (68^circ to 77 F), with excursions permitted up to 30 C. Due to the tablets' hygroscopic nature, they require protection from moisture to maintain stability.

Packaging and Handling

The medication must be kept in the original container or sealed blister packaging and must be dispensed in a tightly closed container. The tablets should not be removed from the blisters until immediately before administration. Consistent with safety requirements, Telmisartan must be stored out of the reach of children.

Disposal

Expired or unused product must be disposed of correctly and according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagAustria

flagLebanon

Equivalent of Telmicard found in:

A-Z Index: